Journal
JOURNAL OF BONE AND MINERAL RESEARCH
Volume 17, Issue 1, Pages 172-178Publisher
WILEY
DOI: 10.1359/jbmr.2002.17.1.172
Keywords
estrogen; bone turnover; postmenopausal bone loss
Categories
Funding
- NCRR NIH HHS [M01 RR00585] Funding Source: Medline
- NIA NIH HHS [AG04875] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [P01AG004875] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Although median levels of bone turnover are increased in postmenopausal women, it is unclear whether the low circulating levels of endogenous estrogen exert a regulatory role on these levels. This issue was evaluated by assessing the effect of a blockade of estrogen synthesis on bone turnover markers in 42 normal women (mean age +/- SD, 69 +/- 5 years) randomly assigned to groups receiving the potent aromatase inhibitor letrozole or placebo for 6 months. Letrozole treatment reduced serum estrone (E-1) and estradiol (E-2) to near undetectable levels (p < 0.0001). This treatment did not affect bone formation markers but, as compared with the placebo group, increased bone resorption markers (urine 24-h pyridinoline [PYD] by 13.3% [p < 0.05] and 24-h urine deoxypyridinoline [DPD] by 14.2% [p < 0.05]) and decreased serum parathyroid hormone (PTH) by 22% (p = 0.002). These data indicate that in late postmenopausal women even the low serum estrogen levels present exert a restraining effect on bone turnover and support the concept that variations in these low levels may contribute to differences in their rate of bone loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available